Janux Therapeutics (JANX) Accumulated Depreciation (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Accumulated Depreciation data on file, last reported at $7.4 million in Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $7.4 million, up 34.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 million (up 34.38% YoY), and the FY2025 annual result was $7.0 million, up 40.69% from the prior year.
• Accumulated Depreciation climbed to $7.4 million in Q1 2026 per JANX's latest filing, from $7.0 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $7.4 million in Q1 2026 and troughed at $212000.0 in Q1 2022.
• A 5-year average of $3.5 million and a median of $3.4 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2026: Accumulated Depreciation soared 759.09% in 2022, then jumped 34.38% in 2026.
• A 5-year view of Accumulated Depreciation shows it stood at $972000.0 in 2022, then jumped by 199.79% to $2.9 million in 2023, then soared by 69.94% to $5.0 million in 2024, then soared by 40.69% to $7.0 million in 2025, then increased by 5.53% to $7.4 million in 2026.
• Business Quant data shows JANX's Accumulated Depreciation at $7.4 million in Q1 2026, $7.0 million in Q4 2025, and $6.5 million in Q3 2025.